Find clinical trials for Multiple Myeloma in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near Hanyang, Seoul, KOR:
(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...
Phase 3
Seoul, Korea, Republic of and 145 other locations
of belantamab (bela) in participants with relapsed or refractory multiple myeloma (RRMM).Part 2: The primary purpose of this part i...
Phase 1
Seoul, Korea, Republic of and 16 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
Seoul, Korea, Republic of and 34 other locations
of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...
Phase 1
Seoul, Korea, Republic of and 21 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of and 210 other locations
(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...
Phase 3
Seoul, Korea, Republic of and 150 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Seoul, Korea, Republic of and 25 other locations
with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).All eligible subjects must be previously treate...
Phase 1, Phase 2
Seoul, Korea, Republic of and 53 other locations
with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...
Phase 3
Seoul, Korea, Republic of and 256 other locations
(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...
Phase 3
Seoul, Korea, Republic of and 129 other locations
Clinical trials
Research sites
Resources
Legal